CPC C12Q 1/6883 (2013.01) [A61K 31/616 (2013.01); C12Q 1/6876 (2013.01); G01N 33/92 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/172 (2013.01); G01N 2333/775 (2013.01); G01N 2500/04 (2013.01); G01N 2800/32 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01)] | 16 Claims |
1. A method comprising:
(a) determining the identity of a single nucleotide polymorphism at position chromosome 6:160880877 (March 2006 assembly—NCBI build 36.1; rs3798220 dbSNP @ NCBI) of an apolipoprotein(a) (Apo(a)) gene in a human subject,
wherein the presence of cytosine or guanine at position chromosome 6:160880877 indicates responsiveness to acetylsalicylic acid,
wherein the presence of thymine or adenine at position chromosome 6:160880877 indicates non-responsiveness to acetylsalicylic acid; and
(b) administering acetylsalicylic acid to a human subject responsive to acetylsalicylic acid to reduce the risk of a cardiovascular event, or
administering an antiplatelet or antithrombotic agent that is not acetylsalicylic acid to a human subject non-responsive to acetylsalicylic acid to reduce the risk of a cardiovascular event.
|